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Background: Immunohistochemical staining for mismatch repair proteins is efficient and widely used to identify
mismatch repair defective tumors. The tumors typically show uniform and widespread loss of MMR protein staining.
We identified and characterized colorectal cancers with alternative, heterogenous mismatch repair protein staining
in order to delineate expression patterns and underlying mechanisms.
Methods: Heterogenous staining patterns that affected at least one of the mismatch repair proteins MLH1, PMS2,
MSH2 and MSH6 were identified in 14 colorectal cancers. Based on alternative expression patterns macro-dissected
and micro-dissected tumor areas were separately analyzed for microsatellite instability and MLH1 promoter methylation.
Results: Heterogenous retained/lost mismatch repair protein expression could be classified as intraglandular (within or
in-between glandular formations), clonal (in whole glands or groups of glands) and compartmental (in larger tumor
areas/compartments or in between different tumor blocks). These patterns coexisted in 9/14 tumors and in the majority
of the tumors correlated with differences in microsatellite instability/MLH1 methylation status.
Conclusions: Heterogenous mismatch repair status can be demonstrated in colorectal cancer. Though rare, attention to
this phenomenon is recommended since it corresponds to differences in mismatch repair status that are relevant for
correct classification.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1771940323126788
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Mismatch repair (MMR) defects characterize 2-4% of
colorectal cancers linked to Lynch syndrome and 15% of
sporadic colorectal cancers caused by epigenetic MLH1
promoter methylation. Various strategies can be used to
preselect colorectal cancers for MMR protein testing,
e.g. clinical guidelines for hereditary cancer, MMR pre-
diction models that combine clinical and pathological
information and potentially novel biomarker-based
strategies [1-5].
Universal assessment of immunohistochemical MMR
staining is increasingly applied in colorectal cancer diag-
nostics in order to identify cases suspected of Lynch* Correspondence: patrick.joost@med.lu.se
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unless otherwise stated.syndrome for further molecular diagnostics and to ob-
tain treatment-predictive information linked to somatic
methylation of MLH1 [6].
The monoclonal antibodies used for immunohisto-
chemical MMR protein staining generally result in stable
and consistent staining patterns with retained staining
or loss of staining. Functional interaction between the
MLH1/PMS2 and the MSH2/MSH6 proteins implies
that the expression pattern of the heterodimerizing pro-
tein partner may be used to direct mutation analysis.
Aberrant MMR function typically leads to complete loss
of nuclear staining in the tumor cells, particularly when
linked to MLH1 promoter hypermethylation that leads
to complete gene silencing [7]. In Lynch syndrome, the
multitude of disease-predisposing mutations may have
variable effects on epitope expression, from complete
loss to weak or retained expression for one or bothtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion may also result in alternative expression patterns,
e.g. cytoplasmic staining and perinuclear staining, which
are typically present throughout the tumor [10]. MMR
protein immunostainings are generally stable and rela-
tively easy to interpret; though challenges and pitfalls
have been reported with false positive as well as false
negative interpretations [10-12]. Most commonly, these
observations relate to technical artifacts caused by sub-
optimal fixation or paraffin-embedding, necrotic areas,
sample storage, antibody specificity, clone selection or
staining conditions [13,14]. Also, neoadjuvant chemo-
therapy and radiotherapy may influence the results with
a particular effect on MSH2/MSH6 staining [15,16].
Heterogenous expression patterns with retained staining
in the adenomatous part and loss of staining in a smaller,
invasive part of the tumor have been reported but their
relevance is uncertain [17]. We systematically collected
colorectal cancers with heterogenous MMR protein
staining patterns for detailed analysis with correlations
e.g. to MSI status and MLH1 promoter methylation.Methods
Materials
Colorectal cancers with heterogenous MMR protein ex-
pression were identified during evaluations at the Depart-
ments of Pathology, Helsingborg Hospital, Sweden and
Hvidore Hospital, Denmark. Following the first observation
of heterogenous MMR protein staining in 2007, two gastro-
intestinal pathologists (PJ and SH) collected all such cases
identified at these two institutions during 5 years. In total,
14 colorectal cancers with heterogenous MMR protein ex-
pression were identified for in-depth analysis (Table 1). TheTable 1 Summary of clinical and pathological data
Case Sex/Age Tumor location Histologic type
1 F/57 Cecum Adca
2 F/33 Cecum Mucinous adca
4 M/41 Rectum Adca
5 F/63 Transverse colon Mucinous adca
6 F/82 Rectum Mucinous adca
8 M/85 Cecum Adca
9 M/71 Ascending colon Mucinous adca
10 F/66 Ascending colon Mucinous adca
11 F/57 Descending colon Adca
12 F/55 Ascending colon Adca
14 M/82 Ascending colon Adca
15 M/83 Ascending colon Adca
16 M/74 Transverse colon Mucinous adca
17 F/74 Cecum Adca
F: female; M: Male; Adca: adenocarcinoma; MMR: mismatch repair.materials consisted of resection specimens from 12 colon
cancers and 2 rectal cancers. None of the patients had
received neoadjuvant radiotherapy or chemotherapy. All
cases were histologically re-evaluated by one pathologist
(P.J.). Tumor stage was determined according to the
American Joint Cancer Committee/Union Internationale
Contre le Cancer (AJCC/UICC) staging system and the
grade according to the WHO system. Mucinous cancers
were considered poorly differentiated. A tumor was
classified as mucinous cancer if more than 50% of the
tumor area showed such differentiation [18]. Tumors with
mucinous components that encompassed <50% of the area
were classified as having a mucinous component, though
not fulfilling the criteria for mucinous tumors [19].
Mucinous cancer was observed in 6 cases. MMR gene mu-
tation testing had been performed in 8 cases, 4 of which
carried disease-predisposing mutations. Ethical approval for
the study was granted from the ethical committees at Lund
University, Sweden and at the Capital Region, Copenhagen.MMR protein immunostaining
Sections from all tumor blocks (n = 4-11) from the 14 cases
were subjected to independent MMR protein staining using
alternative MMR protein antibodies from other manufac-
turers (Table 2). Fresh 4-μm sections from formalin-fixed,
paraffin-embedded tumors were mounted on Dako REAL™
Capillary gap microscope slides (Dako, Glostrup,
Denmark). The slides were dried overnight at room
temperature and thereafter at 60°C for 1–2 hours. The
tissue was deparaffinized in xylene for two times
5 min, followed by 5 min each in 99.5% and 95% etha-
nol and 5 min in distilled water. Heat-induced epitope
retrieval was achieved by pressure boiler-treatment inDifferentiation pTNM Stage MMR gene mutation
Moderate T2N0MX I Not tested
Poor T2N0MX I MSH2
Moderate T3N0MX II MSH6
Moderate T4N1MX III Not tested
Moderate T2N0MX I Not identified
Poor T4N0MX II Not identified
Poor T3N0MX II Not tested
Poor T3N0MX II Not identified
Moderate T3N0MX II MSH6
Poor T3N0MX II MLH1
Moderate T3N0MX II Not tested
Moderate T3N0MX II Not tested
Poor T3N1MX III Not tested
Poor T3N1MX III Not identified
Table 2 Information on the MMR protein antibodies used
MMR protein Lab Supplier Clone Dilution Immunogen/epitope
MLH1 L BD Pharmingen G168-15 1:100 Full-length
C DAKO ES05 RTU Recombinant protein, 210 aa
L DAKO ES05 1:100 Recombinant protein, 210 aa
PMS2 L BD Pharmingen A16-4 1:300 aa 431–862, C-terminal
H Ventana (Cell Marque) EPR3947 RTU 100 aa, C-terminal
C Epitomics EPR3947 1:50 100 aa, C-terminal
MSH2 L Calbiochem FE11 1:100 C-terminal
H Ventana (Cell Marque) G219-1129 RTU Full-length
C Novocastra 25D12 1:50 Full-length
MSH6 C Epitomics EP49 1:100 Synthetic peptide, N-terminal
L Epitomics EP3945 1:100 Synthetic peptide, N-terminal
L BD Transduction Lab. 44 1:500 Synthectic peptide aa 225-333
MMR: mismatch repair; L: Lund; H Helsingborg; C: Copenhagen; RTU: ready to use.
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(1:10 mM, pH 9.0) for 20 min. Hereafter, the slides
were cooled for 20 min and rinsed in distilled water.
Immunostaining was performed using the Dako Auto-
stainer and the EnVision™ visualization method (Dako,
Glostrup, Denmark). Endogenous peroxidase activity
was blocked for 5 min and primary mouse monoclonal
IgG antibodies were used (Table 2). Following primary
antibody incubation, the slides were incubated with
EnVision™/horseradish peroxidase (HRP) rabbit/mouse
(Dako) and stained using the EnVision™ Detection Sys-
tem peroxidase/DAB rabbit/mouse (Dako). The immu-
nohistochemical stainings were classified as retained,
lost or reduced, i.e. a weaker than expected staining in
the tumor cells compared to the stromal cells. The
areas of the respective expression patterns were esti-
mated in each block end expressed in percentage.
Microsatellite instability analysis
To assess the impact from heterogenous MMR protein
stainings on MMR protein function, the tumors were
subjected analysis of microsatellite instability (MSI). De-
pending on the extent of the area involved, microdissec-
tion or macrodissction was used to obtain material from
areas with the respective expression patterns (Table 3).
Laser capture micro-dissection was performed using
Polyethylene Teraphthalate (PET)-membrane Frame-
Slides (Carl Zeiss MicroImaging, Germany). In tumors
where larger areas showed variable expression pat-
terns, macro-dissection was performed. Tissue from
2–6 tumor areas with the respective MMR protein
stained patterns were collected from 10-μm tissue sec-
tions. DNA extraction was performed using QIAamp®
DNA micro kit (Qiagen) for laser micro-dissected tis-
sues and using the QIAcube machine (Qiagen) or the
QIAamp® DNA FFPE tissue kit (Qiagen) for macro-dissected tissues or whole tumor sections. MSI ana-
lyses were performed using the MSI Analysis System,
Version 1.2 (Promega, Madison, WI), PCR products
were size separated on a 3130xl Genetic Analyzer
(Applied Biosystems, Foster City, CA). The results were
evaluated using the GeneMapper® software Version 4.0
(Applied Biosystems, Foster City, CA). The analysis in-
cluded the 5 mononucleotide markers BAT-25, BAT-26,
NR-21, NR-24, and MONO-27 (Promega, MSI Analysis
System, Version 1.2, Madison, WI). Tumors with instability
for 1 marker were classified as MSI low, tumors with
instability for ≥2 markers were classified as MSI-high
(MSI-H), and tumors with stability for all markers were
classified as microsatellite stable (MSS).
Methylation-specific PCR analysis
Extracted DNA was treated with bisulfite using the EZ
DNA Methylation-Lightning™ Kit (Zymo Research, CA,
USA) according to the manufacturer’s instructions.
MLH1 promoter methylation status was analyzed by
means of a fluorescence-based, real-time methylation-
specific PCR assay, as described previously [20]. Two
sets of primers and probes, designed specifically for
bisulfite-converted DNA, were used: MLH1-M2B for the
methylation-specific reaction [21] and ALU-C4 for the
methylation independent control reaction used to meas-
ure the amount of bisulfite-converted input DNA [22].
Amplification was performed on QuantStudio™ 12 K Flex
Real-Time PCR System (Life Technologies). Samples were
run in duplicate, including positive and negative controls.
Flow cytometry
Flow cytometric DNA analysis was performed as previ-
ously described [23,24]. The separated cells were then
treated with ribonuclease (Sigma-Aldrich, Stockholm,
Sweden), incubated with trypsin for 48 h (Merck,













MLH1 PMS2 MSH2 MSH6
1 1A¤/* + CL 15 +/− +/− + + 0/5 and 4/5 +/−
1B + CL 5 - - +/R +/−
1C - H 0 - - + +
1D - H 0 - - + +
1E¤ + CL, IG 70 / 10 +/− +/− +/R +/− 0/3 vs 4/5
2 24 - H 0 + + + + -
25* - H 0 + + + + 0/5
26 - H 0 + + + +
27* - H 0 + + + + 0/5
28 + CL, IG 15 +/− +/− + +
29* + CL, IG 40 +/− +/− + + 5/5
30 + IG 10 +/− +/− + +
31 + IG 5 +/− +/− + +
32 + IG 5 +/− +/− + +
4 2 + IG 97 + + +/− R/- NE
3¤/* + CL, IG 95 + + +/− R/- 3/3 vs 3/5
4 + CL, IG 80 + + +/− R/-
5* + IG 95 + + +/− R/- 5/5
5 20* + CL, IG 50 / 100 + +/− - R/- 5/5 -
21 + IG 100 + + - R/-
23 + IG 100 + + - R/-
24 + IG 100 + + - R/-
25 + COM, IG 100 + - - R/-
26 + COM, IG 100 + - - R/-
27 + COM IG 100 + - - R/-
28 + COM, IG 100 + - - R/-
29 + COM, IG 100 + - - R/-
30 + COM, IG 100 + - - R/-
31 + COM, IG 100 + - - R/-
6 5¤ + IG 100 + R/- + + 0/5 vs 0/4 NE
6* + IG 100 + R/- + + 0/5
7* - H 0 + + + + 0/5
8* + IG 100 + R/- + + 0/5
9* + IG 95 + R/- + + 0/5
10 + IG 95 + R/- + +
11* + IG 100 + R/- + + 0/5
8 5* - H 0 - - + + 5/5 +
6 + CL, IG 60 - - + R/-
7 + CL 20 - - + +/−
8 - H 0 - - + +
9 - H 0 - - + +
10 + CL, IG 20 - - +/R +/−
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Table 3 Summary of MMR heterogeneity (Continued)
11 - H 0 - - + +
12 + CL 20 - - +/− +/−
9 16 - H 0 + + + + +
19 - H 0 + + + +
20* - H 0 + + + + 0/5
21* - COM 100 - - + + 5/5
22 - H 0 + + + +
40 - H 0 + + + +
44 - H 0 + + + +
10 6 + CL 50 - - +/− +/− +
7 - H 0 - - + +
8 - H 0 - - + +
9* - H 0 - - + + 5/5
10 - H 0 - - + +
11 - H 0 - - + +
11 3 - H 0 - - + + +
4 + CL, IG 5 - - +/− +/−
5 - H 0 - - + +
6* - H 0 - - + + 5/5
7 - H 0 - - + +
8* + CL, IG 30 - - +/R +/− 5/5
12 3* + CL 5 - - +/− +/− 5/5 +
4 + CL, IG 90 - - +/− +/−
5 + CL, IG 80 - - +/− +/−
6 - H 100 - - - -
7 + CL 60 - - +/− +/−
8 + CL, IG 90 - - +/− +/−
9* + CL, IG 60 - - +/− +/− 5/5
14 1A* - H 0 - - + + 5/5 +
1B* + CL 5 - - +/R +/− 5/5
1C* + CL, IG 30 - - R/- +/− 5/5
1D* + CL 40 - - +/R +/− 5/5
1E* + CL, IG 40 - - R/- +/− 5/5
15 4A* + IG 100 + + +/R R/- 5/5 NE
4B* + IG 100 + + + R/- 5/5
4C + IG 100 + + +/R R/-
4D + IG 100 + + + R/-
4E + IG 100 + + +/R R/-
16 6A + IG 15 - - R +/− +
6B* + CL 3 - - +/R +/− 5/5
6C + CL 10 - - +/R +/−
6D + IG 5 - - R +/−
6E + IG 5 - - +/R +/−
17 18* + CL 55 - - +/− +/− 5/5 +
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Table 3 Summary of MMR heterogeneity (Continued)
19 - H 0 - - + +
20 + CL 8 - - +/− +/−
21 - H 0 - - + +
22 - H 0 - - + +
microdissection; *: macrodissection; CL: clonal, IG: intraglandular; COM: compartmental; H: homogenous; R: reduced staining; +/-: heterogenous staining; MMR:
mismatch repair; MSI: microsatellite instability; NE: not evaluated.
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ide (Sigma-Aldrich, Stockholm). Flow cytometric DNA
analysis was performed in a FACS Caliber (Becton, Dick-
inson, BD Biosciences, USA). Up to 20,000 nuclei were
analysed from each sample. The DNA histograms ob-
tained were automatically processed using Modfit LT
3.3™ software. The DNA index (DI) was calculated as the
ratio of the respective modal channel values of the non-
diploid and the diploid G0/G1 peaks. The S-phase frac-
tion (Spf) was estimated assuming that the S-phase
compartment constituted a rectangular distribution be-
tween the modal values of the G0/G1 and G2 peaks.
Results
Immunohistochemical staining using alternative MMR pro-
tein antibodies confirmed heterogenous MMR protein ex-
pression in all 14 tumors. Heterogenous expression affected
MLH1/PMS2 in 3 tumors, PMS2 in 2 tumors, MSH2/
MSH6 in 10 tumors (of which two also expressed hetero-
geneity for MLH1/PMS2) and MSH6 only in 1 tumor (in
which one block also expressed heterogeneity for
PMS2). Areas with alternative expression patterns wereFigure 1 Examples of the different MMR protein staining patterns. A) clo
loss and D) compartmental loss with different patterns in two separate tumor bwell demarcated and appeared in three distinct pat-
terns: “intraglandular” (retained/lost staining within or
in between glandular formations), “clonal” (retained/
lost staining in whole glands or groups of glands) and
“compartmental” (retained/lost staining in larger tumor
areas/compartments leading to retained/lost staining in
between different tumor blocks) (Figure 1, Table 3). Various
heterogenous expression patterns co-existed in 9/14 tu-
mors, most commonly as intraglandular and clonal hetero-
geneity (figure 1c). The heterogenous staining patterns
were present in 3-100% of the examined tumor area. In 4/
14 cases, all tumor blocks showed heterogeneity, whereas
the remaining tumors showed heterogeneity in a variable
fraction of the tumor blocks (Table 3).
MSI was demonstrated in 13/14 tumors. Intra-tumor
differences in MMR status, i.e.MSI versus MSS, in line
with MMR protein staining expression was observed in
3 tumors (Table 3; case 1, 2 and 9). Non-consistent,
homogenous MSI status in tumors with heterogenous
MMR protein expression was observed in 2 cases
(Table 3; cases 4 and 6). MLH1 promoter methylation
was demonstrated in all 7 cases with complete (non-nal loss, B) intraglandular loss, C) co-existence of clonal and intraglandular
locks.
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cases 1 and 9) heterogenous MMR protein staining for
MLH1/PMS2 correlated with heterogenous MLH1 pro-
moter methylation, i.e. tumor areas with retained MLH1
expression did not show MLH1 methylation, whereas
areas with loss of MLH1 expression showed MLH1
methylation. Concordant immunostaining and methyla-
tion status suggest functional intratumoral heterogeneityFigure 2 An adenocarcinoma (case 1) with 4 different expression pat
PMS2 and heterogeneity/retained expression for MSH2/MSH6. A) clon
MSS corresponding to retained MMR protein staining. Methylation analysis
methylation, which verifies clonal MLH1 methylation status. Flow cytometri
and G) 1.57 in the MSS area.(Figure 2). DNA flow cytometric analysis was performed
in one tumor (case 1) and demonstrated differences in
DNA content within the heterogenous areas, which had
DNA indices of 1.13 and 1.57, respectively (Figure 2).
Discussion
Heterogeneous MMR protein expression is a rare
phenomenon, but corresponds to differences in MMRterns and various combinations of heterogeneity, loss of MLH1/
al loss of MLH1 staining. B) MSI corresponding to loss of staining, C)
revealed D) presence and E) absence, respectively, of MLH1 promoter
c analysis showing different DNA indices, i.e. F) 1.13 in the MSI area
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recognize to prevent false-positive or false-negative eval-
uations. We identified three distinct patterns of hetero-
geneity, i.e. intraglandular, clonal and compartmental
heterogenous MMR protein expression. The different
patterns co-existed within the same tumor and the ex-
tent of the tumor involved varied. In-depth analysis
suggests that multiple causes may apply, e.g. variable
epitope expression, expression related to variable differ-
entiation, second hit mutations or methylation in se-
lected tumor clones and possibly influence from factors
linked to the tumor microenvironment such as hypoxia
and oxidative stress [25].
Intraglandular and/or clonal heterogeneity throughout
the tumor, which may be caused by variable epitope ex-
pression, was identified in 4 tumors (cases 4, 5, 15 and
16, Table 3). Homogenous loss of MLH1/PMS2 and
heterogenous expression of MSH2/MSH6 was identified
in 7 tumors that were consistently MSI and showed
MLH1 promoter methylation (Table 3). This expression
pattern has previously been observed and may relate
either to a germline MSH2/MSH6 mutation that allows
for partial epitope binding in the presence of somatic
MLH1 methylation or to secondary MSH2/MSH6 inacti-
vation [25-27]. Heterogenous MLH1 and/or PMS2 expres-
sion, suggestive of variable MLH1 methylation/second hit
mutations was observed in 2 tumors (case 2 and 6, Table 3).
Case 1 showed a more complex pattern of MMR protein
expression and intra-tumor differences in MSI, MLH1Figure 3 Variable MMR protein expression in relation to tumor differ
tumor component and loss of PMS2 expression in a non-mucinous compo
in the adenomatous component of the tumor, whereas the remaining tum
heterogeneity for MLH6 in a poorly differentiated tumor component and hpromoter methylation and DNA content, suggestive of a
tumor composed of two distinct clones (case 1, Figure 2).
Variable MMR status did in some tumors correspond
to variable differentiation, e.g. mucinous areas (cases 5
and 15), poor differentiation (cases 16 and 17) or aden-
omatous components (case 2, Figure 3). Correlation be-
tween MSI status and expression also of other molecular
markers has been described [28,29]. Different, through
homogenous, MMR protein expression patterns in dis-
tinct tumor compartments were observed in a mucinous
adenocarcinoma (case 9) with loss of MLH1/PMS2 expres-
sion, MSI and MLH1 methylation in 1/7 tumor blocks that
corresponded to an adenomatous tumor component
(Figure 1d). Sample mix was excluded through histologic
review and penta-D marker fragment analysis (data not
shown). Homogenous loss/reduced staining of MSH2/
MSH6 throughout the tumor and additional loss of PMS2
in 7/10 tumor blocks was observed in a mucinous adeno-
carcinoma (case 5). This case most likely reflects how the
mucinous tumor component progressed in another line
than the non-mucinous tumor component. Though com-
partmental loss of MMR protein expression is rare, this ob-
servation motivates thorough evaluation of different tumor
compartments, particularly when areas with variable ex-
pression are identified.
Limitations to our study include analysis based on surgi-
cal specimens though biopsy material may produce stain-
ings of better technical quality [30-33]. At the same time
use of biopsy material implies analysis of a restricted tumorentiation. A) case 5 with retained expression for PMS2 in a mucinous
nent. B) case 2 with clonal and intraglandular heterogeneity for MLH1
ors showed retained expression for MLH1. C-D) case 17 with clonal
omogenous expression in a well-differentiated tumor component.
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Also, information on MMR gene mutation status was not
available in all cases. The 4 tumors from Lynch syndrome
mutation carriers, however, expressed heterogeneity in be-
tween different tumor blocks, which showed homogenous
as well as heterogenous loss in clonal and intraglandular
patterns. Recognition of so-called “patchy” MMR protein
staining has been reported and were also considered herein
(Table 3). This phenomenon differs from the heterogenous
staining patterns described herein in that it primarily relates
to MSH6 stainings, neoadjuvant treatment [15,16] or repre-
sents a weak or cytoplasmic staining rather than the distinct
and well-demarcated areas of retained staining and loss of
staining described herein.
Conclusions
Our study verifies heterogenous MMR status in a subset
of colorectal cancer. Heterogenous MMR protein ex-
pression appears in three major forms, which frequently
co-exist and correlate to differences in MMR status. We
suggest that variable MMR protein staining patterns
should be considered and when observed linked to ex-
tended analysis in order to ensure correct classification
of MMR status.
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